Contact Us Location
JP EN
JAPANESE ENGLISH

Clinical Trials

Clinical Trials

Investigator-driven clinical research has a central role
in our efforts to improve breast cancer treatment.
A particular focus is translational research to develop new,
tailored therapies to achieve the best outcome for individual patients.
Several of our clinical trials are being conducted in collaboration
with international research organizations.

POSITIVE (JBCRG-23)
No Longer Recruiting
GLOBAL This trial is a collaborative study with IBCSG.
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy
JBCRG-M07 (FUTURE)
No Longer Recruiting
Fulvestrant with additional palbociclib in advanced or metastatic HR-positive HER2-negative breast cancer after progression to fulvestrant monotherapy. -FUTURE trial a multicenter study-
JBCRG-24 (PALLAS)
No Longer Recruiting
GLOBAL PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone rec
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone rec
JBCRG-M06 (EMERALD)
No Longer Recruiting
A phase III clinical study to compare the combination therapy of eribulin mesylate + pertuzumab + trastuzumab with paclitaxel or docetaxel + pertuzumab + trastuzumab
JBCRG-22 (Neo-Entrance)
No Longer Recruiting
A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)
OlympiA
No Longer Recruiting
GLOBAL This trial is a collaborative study with BIG.
A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment
JBCRG-M05 (PRECIOUS)
No Longer Recruiting
A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer（Study of Perjeta re-treatment for clinical outcomes）
JBCRG-20 (Neo-peaks)
No Longer Recruiting
A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer(Neo-peaks study)
JBCRG-C06
No Longer Recruiting
Investigation of optimal regimen of Fulvestrant in patients with postmenopausal ER-positive advanced recurrent breast cancer
PENELOPE (JBCRG-21)
No Longer Recruiting
GLOBAL This trial is a collaborative study with GBG.
Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy“PENELOPEB”
Previous Page Next Page
Research by
Voluntary Organization JBCRG